TY - JOUR
T1 - Targeting angiogenesis in colorectal cancer tyrosine kinase inhibitors
AU - Kircher, Sheetal Mehta
AU - Nimeiri, Halla S.
AU - Benson, Al B.
N1 - Publisher Copyright:
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2016
Y1 - 2016
N2 - Colorectal cancer is commonly diagnosed throughout the world, and treatment options have greatly expanded over the last 2 decades. Targeting angiogenesis has been a major focus of study in a variety of malignancy types. Targeting angiogenesis has been achieved by several mechanisms in colorectal cancer, including use of antiangiogenic small molecule tyrosine kinase inhibitors (TKIs). There have been many attempts and failures to prove efficacy of TKIs in the treatment of colorectal cancer including sorafenib, sunitinib, vatalanib, and tivozanib. Regorafenib was the first TKI to demonstrate efficacy and is an orally active inhibitor of angiogenic (including the vascular endothelial growth factor receptors 1, 2, and 3), stromal, and oncogenic receptor tyrosine kinases. There are ongoing investigations of both regorafenib and ninetanib; however, there remains a critical need to better understand novel combinations with TKIs that could prove more efficacious than available options.
AB - Colorectal cancer is commonly diagnosed throughout the world, and treatment options have greatly expanded over the last 2 decades. Targeting angiogenesis has been a major focus of study in a variety of malignancy types. Targeting angiogenesis has been achieved by several mechanisms in colorectal cancer, including use of antiangiogenic small molecule tyrosine kinase inhibitors (TKIs). There have been many attempts and failures to prove efficacy of TKIs in the treatment of colorectal cancer including sorafenib, sunitinib, vatalanib, and tivozanib. Regorafenib was the first TKI to demonstrate efficacy and is an orally active inhibitor of angiogenic (including the vascular endothelial growth factor receptors 1, 2, and 3), stromal, and oncogenic receptor tyrosine kinases. There are ongoing investigations of both regorafenib and ninetanib; however, there remains a critical need to better understand novel combinations with TKIs that could prove more efficacious than available options.
KW - Angiogenesis inhibitors
KW - Colorectal neoplasms
KW - Drug therapy
KW - Protein-tyrosine kinases
UR - http://www.scopus.com/inward/record.url?scp=84978187241&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978187241&partnerID=8YFLogxK
U2 - 10.1097/PPO.0000000000000192
DO - 10.1097/PPO.0000000000000192
M3 - Review article
C2 - 27341596
AN - SCOPUS:84978187241
SN - 1528-9117
VL - 22
SP - 182
EP - 189
JO - Cancer Journal (United States)
JF - Cancer Journal (United States)
IS - 3
ER -